Verastem Inc

Verastem Inc. a development-stage biopharmaceutical company focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766 a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201 an adaptive two-part multicenter parallel cohort randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202 which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem Inc. has license agreements with Chugai Pharmaceutical Co. Ltd. for the development commercialization and manufacture of products containing avutometinib; and Pfizer Inc. to research develop manufacture and commercialize products containing Pfizer's inhibitors of FAK for therapeutic diagnostic and prophylactic uses in humans. In addition it has clinical collaboration agreement with Amgen Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham Massachusetts.